

COPY OF PAPERS
ORIGINALLY FILED

AUG 14 2002

PTO/SB/92 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Certificate of Mailing under 37 CFR 1.8

RECEIVED

AUG 19 2002

TECH CENTER 600/2900

In the Application of: Carter et al

CASE NO.: PH-7268

APPLICATION NO.: 10/027,505

GROUP ART UNIT: 1614

FILED: DECEMBER 20, 2001

EXAMINER: UNKNOWN

FOR: DIAMINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

I hereby certify that this correspondence - **Preliminary Amendment** is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Assistant Commissioner for Patents
Washington, D.C. 20231

On August 9, 2002
Date

Denise Bierlein

Signature

Denise Bierlein/Depositor

Type or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Burden Hour Statement: This form is estimated to take 0.03 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

AUG 19 2002

COPY OF PAPERS
ORIGINALLY FILED

TECH CENTER 1600/2900



PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN THE APPLICATION OF: Carter et al

CASE NO.: PH-7268

SERIAL NO.: 10/027,505 ✓

GROUP ART UNIT: 1614

FILED: December 20, 2001 ✓

EXAMINER: UNKNOWN

FOR: DIAMINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY ✓

Asst. Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

Preliminary to examination, please amend the above-identified application as follows.

IN THE SPECIFICATION

Please delete line 5 of page 49 and replace with the new paragraph below as follows. ✓

a¹
X is CHR¹⁶NR¹⁷;

Please delete line 25 of page 55 and replace with the new paragraph below as follows. ✓

a²
X is CHR¹⁶NR¹⁷;

IN THE CLAIMS

✓
Please amend claims 8 and 13 as follows.

a³
8. (AMENDED) The compound of claims 1-7, wherein:

B'
cont
X is CHR¹⁶NR¹⁷;